A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary

• Status: RECRUITING
• Trial end date: 2029-07-01

Summary

The goal of this clinical research study is to learn if the combination of atezolizumab and tiragolumab can help to control cancers of unknown primary. The safety and effects of this drug combination will also be studied

• Phase: PHASE2

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborators: Genentech, Inc.; Strategic Alliance
• Treatments: atezolizumab; Tiragolumab